We observed that there was no apparent correlation between dinaciclib response and BRAF/NRAS mutational status, leading us to conclude that dinaciclib had broad-spectrum anti-melanoma activity and was not conclusively mutation specific. This evidence concerns the gene BRAF and melanoma.